Genmab — Januar 2020
-
“With this approval, newly diagnosed patients with multiple myeloma who are eligible for ASCT may have the opportunity for treatment with a DARZALEX-containing regimen. We are extremely pleased that DARZALEX has received this latest approval and we look forward to the combination of DARZALEX plus bortezomib, thalidomide and dexamethasone being launched in Europe,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
The approval was based on the Phase III CASSIOPEIA (MMY3006) study
-
https://www.bbc.com/news/health-51182451 Endnu en historie omkring en kur imod cancer. Lad da håbe at det denne gang er rigtigt.
-
Såvidt jeg kan se er det en gammel historie fra Basel (og ikke Cardiff). Nok lettere tænkt end gjort ? https://elifesciences.org/articles/24476
-
-
God morgen.
-
Den er er også meget sjov og man ser tydligt CWH er intakt https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/81009_sjov.JPG
-
@Stockbull. Tak... Lad os bare holde os til den sidste, så er jeg ikke utilfreds
-
Kkjoel 15.32 and EL 15.51 - my estimates, based on exactly the same growth figures in the US as in 2019 and a sharp reduction in growth ROW will be 4.3 with upside to 4.4. I am lowering ROW growth to one third of growth in 2019. It should be said that SC can mean higher growth rates in 20 than in 19, but I did not take that into consideration, but instead use it to maintain the growth rate of 2019. If SC give an increased growth rate, we should probably go higher.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind